[ET Net News Agency, 19 February 2020] UOB Kay Hian lifted its target price for WuXi
Biologics (Cayman) (02269) to HK$155 from HK$112 and maintained its "buy" rating.
The research house said WuXi Bio has signed a US$3bn vaccine contract with a global
vaccine leader for an initial term from February 2020 to December 2039. The vaccine CDMO
(contract development and manufacturing organisation) project is expected to fuel its
revenue and earnings growth in the long term.
With solid business expansion, WuXi Bio's revenue is expected to increase by 51.9% to
Rmb3,850m in 2019. Of this, both fee-for-services revenue and milestone fee income would
maintain strong growth, driven by continued increase in the number of projects and
increasing average revenue per project. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02269 WUXI BIO
Nominal 
13.740 -0.220 (-1.576%) Research Report
19/02/2020 15:47
{I-bank focus}UOBKH lifts WuXi Biologics (02269) to HK$155
| Remark: | Real time quote last updated: 30/04/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |